Regulation of expression and phosphorylation of A9/alpha 6 beta 4 integrin in normal and neoplastic keratinocytes.
The A9 antigen is a basement membrane antigen of normal squamous epithelial cells that is strongly expressed in many squamous carcinomas. High expression of this antigen is associated with early relapse in squamous cell carcinomas of the head and neck. We now know that the A9 antigen is structurally, immunologically, and functionally similar to the alpha 6 beta 4 integrin that has been shown to be linked to metastatic behavior in murine tumor models. The alpha 6 and beta 4 genes have been cloned and sequenced, and a model has been constructed from the deduced amino acid composition. In this study we present a hypothetical model and use it to design experiments to assess the factors that influence the expression of the A9/alpha 6 beta 4 integrin in normal and malignant keratinocytes. High calcium induces down regulation of A9/alpha 6 beta 4 antigen in normal but not malignant keratinocytes within 24 hours. Although calcium can down-regulate beta 4 message in tumor cells in the absence of epidermal growth factor (EGF), transcription of beta 4 increased in the tumor cells under the conditions we used for assessing antigen expression (calcium plus EGF). Retinoic acid also stimulated transcription of beta 4 in tumor cells, but this was partially inhibited by the presence of high calcium. Phosphorylation of the beta 4 chain was stimulated by epidermal growth factor and calcium in normal keratinocytes, but in the malignant cells phosphorylation was constant regardless of the culture conditions. Our results indicate that high expression of the alpha 6 beta 4 integrin is associated with conditions that favor migration and undifferentiated proliferation of normal keratinocytes and that malignant keratinocytes differ from normal keratinocytes by constitutive phosphorylation of beta 4 and by failure to downregulate beta 4 transcription in response to calcium in the presence of EGF.
Carey
T E
TE
Laboratory of Head and Neck Cancer Biology, University of Michigan, Ann Arbor 48109-0506.
Laurikainen
L
L
Nair
T S
TS
Reinke
T S
TS
Coling
D E
DE
Wolf
G T
GT
Van Waes
C
C
Liebert
M
M
Marcelo
C
C
D000951:Antigens, Neoplasm / Q000378:metabolism*; D015152:Blotting, Northern; D002118:Calcium / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D002455:Cell Division; D004815:Epidermal Growth Factor / Q000494:pharmacology; D006801:Humans; D016023:Integrins / Q000378:metabolism*; D015603:Keratinocytes / Q000276:immunology*; D008958:Models, Molecular; D009062:Mouth Neoplasms / Q000276:immunology*; D010766:Phosphorylation; D011510:Proteolipids / Q000235:genetics / Q000378:metabolism*; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D014158:Transcription, Genetic; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D016023:Integrins; D011510:Proteolipids; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants; D012333:RNA, Messenger; D014212:Tretinoin; D004815:Epidermal Growth Factor; D002118:Calcium